HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch

FDA slaps Dr. Reddy's Hyderabad biologics plant with seven observations in new Form 483

The agency spotted seven observations at Dr. Reddy's Bachupally, Hyderabad, biologics plant following a mid-June inspection.

By FiercePharma · Jun 27, 2026 · via FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
Fierce Biotech Layoff Tracker 2026: Biogen sheds Apellis R&D roles; ADC Tx slims workforce
The WeekFierceBiotech ↗
As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial tea…
Jun 27, 2026
EU Opens Antitrust Proceedings Against Sanofi Over Efluelda Marketing
The WeekBriefing
The European Commission has launched formal antitrust proceedings into Sanofi’s flu vaccine marketing. The cas…
Jun 27, 2026
BIO 2026: AI, federal policy impacts, and general vibes
The WeekSTAT News ↗
What were the vibes like at BIO 2026? STAT reporters take you inside the annual industry conference on the lat…
Jun 26, 2026